Genes Without Patents
To Chris Hansen, the American Civil Liberties Union (ACLU) lawyer who led the lawsuit against Myriad Genetics’ patents of two human breast cancer genes, BRCA1 and BRCA2, the exchange augured well for the case’s outcome. The line of questioning seemed to bolster the ACLU’s argument that the genes were a product of nature, like a kidney, and so by law, not patentable. In isolating the genes for breast cancer, it argued, Myriad invented nothing that wasn’t already there.
Printer-friendly version
Send by email